Create account

Coverage dated October 26, 2026

STAT+: GSK sees its return to cancer starting to pay off

Headline from STAT

A decade ago, GSK was out of oncology. It could soon pick up approval for its sixth cancer drug.

STAT's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Read the reports

Reports & sources

2 articles, oldest first.

  1. Bloomberg

    GSK’s Big Cancer Swing Begins to Pay Off With Promising Data (opens Bloomberg)

    Published

    Bloomberg's feed description

    GSK Plc’s return to cancer is beginning to show signs of paying off.

  2. STAT

    STAT+: GSK sees its return to cancer starting to pay off (opens STAT)

    Published

    STAT's feed description

    A decade ago, GSK was out of oncology. It could soon pick up approval for its sixth cancer drug.

STAT+: GSK sees its return to cancer starting to pay off | Since Then